Original Article

Clinical Pharmacy Services in a Neurosurgical Intensive Care Unit in Iran: A Focus on a Comprehensive Medication Management Model

Abstract

Background: Critically ill patients treated in the intensive care unit (ICU) are at risk of drug-related problems (DRPs), clinical pharmacists are specifically trained in pharmacotherapy evaluations with the abilities to identify and manage drug-related complications. This study aims to identify areas where clinical pharmacists can be effective in the ICU. The primary outcomes of this study were determining the clinical aspect of clinical pharmacists in the ICU, type, and number of clinical pharmacist interventions. Methods: This was a prospective, interventional study in a teaching hospital in Iran. A clinical pharmacist was dedicated to implement comprehensive medication management (CMM); All Pharmacotherapy Problems were categorized. Results: During the monitoring of 162 patients by the clinical pharmacist, 1524 interventions were conducted. The most frequent pharmacotherapy-related problems identified were drug selection (33.3%), dose adjustment (17.3%), and fluid and electrolyte management (12.9%). Conclusion: Clinical pharmacists’ interventions could reduce the rate of DRPs by pharmacotherapy evaluation and may have important role in many aspects of patient’s management.

1. Johansen ET, Haustreis SM, Mowinckel AS, Ytrebø LM. Effects of implementing a clinical pharmacist service in a mixed Norwegian ICU. Eur J Hosp Pharm. 2016;23(4):197-202.
2. Bean CL. Definition of clinical pharmacy. Am J Hosp Pharm. 1979 Jun;36(6):744.
3. Noormandi A, Karimzadeh I, Mirjalili M, Khalili H. Clinical and economic impacts of clinical pharmacists' interventions in Iran: a systematic review. Daru. 2019;27(1):361-378.
4. Jacobi J. Clinical pharmacists: practitioners who are essential members of your clinical care team. Revista Médica Clínica Las Condes. 2016;27(5):571-577.
5. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955-964.
6. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69(5):543-552.
7. Dequito AB, Mol PG, van Doormaal JE, et al. Preventable and non-preventable adverse drug events in hospitalized patients. Drug Saf. 2011;34(11):1089-1100.
8. Gallagher J, Byrne S, Woods N, Lynch D, McCarthy S. Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 2014;14(1):177.
9. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002-2012.
10. Schatz S, Weber R. Adverse drug reactions. Pharma Pract. 2015;1:1.
11. Pharmaceutical Care Network Europe (PCNE). Drug-related problems classifications available from: https://www.pcne.org/conference/3/pcne-working-symposium-2009.
12. Bourne RS, Dorward BJ. Clinical pharmacist interventions on a UK neurosurgical critical care unit: a 2-week service evaluation. Int J Clin Pharm. 2011;33(5):755.
13. McBane SE, Dopp AL, Abe A, et al. Collaborative drug therapy management and comprehensive medication management-2015. Pharmacotherapy.2015;35(4):e39-50.
14. Mabasa VH, Malyuk DL, Weatherby E-M, Chan A. A standardized, structured approach to identifying drug-related problems in the intensive care unit: FASTHUG-MAIDENS. Can J Hosp Pharm. 2011;64(5):366-9.
15. Splawski J, Minger H. Value of the pharmacist in the medication reconciliation process. P T. 2016;41(3):176.
16. Bosma LB, Hunfeld NG, Quax RA, et al. The effect of a medication reconciliation program in two intensive care units in the Netherlands: a prospective intervention study with a before and after design. Ann Intensive Care. 2018;8(1):19.
17. Marshall J, Finn CA, Theodore AC. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med. 2008;36(2):427-433.
18. Donihi AC, Moorman JM, Abla A, Hanania R, Carneal D, MacMaster HW. Pharmacists' role in glycemic management in the inpatient setting: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. Journal of the American College of Clinical Pharmacy. 2019;2(2):167-176.
19. Mularski KS, Yeh CP, Bains JK, Mosen DM, Hill AK, Mularski RA. Pharmacist glycemic control team improves quality of glycemic control in surgical patients with perioperative dysglycemia. Perm J. 2012;16(1):28.
20. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10.
21. Ratanajamit C, Kaewpibal P, Setthawacharavanich S, Faroongsarng D. Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs. J Med Assoc Thai. 2011;92(11):1500-7.
22. Centers for Disease Control and Prevention. Medication Safety Basics. Last updated June 29, 2018. Atlanta, GA: Centers for Disease Control and Prevention. www.cdc.gov/medicationsafety/basics.html. Accessed November 20, 2018.
23. Papadopoulos J, Rebuck JA, Lober C, et al. The critical care pharmacist: an essential intensive care practitioner. Pharmacotherapy. 2002;22(11):1484-8.
Files
IssueVol 11, No 3 (Summer 2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v11i3.15999
Keywords
Clinical Pharmacy; Intensive Care Unit; Drug Related Problems
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Andarzbakhsh K, Mohebbi N, Rezazadeh A, Gholami K, Abrishami R. Clinical Pharmacy Services in a Neurosurgical Intensive Care Unit in Iran: A Focus on a Comprehensive Medication Management Model. J Pharm Care. 2023;11(3):151-157.